ATLASResMed (RMD) Q1 fiscal 2027 earnings results
ResMed (RMD) reported EPS of $2.91 against an analyst estimate of $2.67: a beat of $0.24 (9.0%). The quarter ended Sep 30, 2026; the company reported on Thursday, October 29, 2026, after the close.
Status: Confirmed · cross-checked Nov 2 · Source: EODHD (calendar and fundamentals, cross-checked)
Notify me when ResMed reports
Track RMD free Add ResMed to a free ATLAS watchlist.
RMD Q1 fiscal 2027 results at a glance
| EPS reported | $2.91 |
|---|---|
| EPS estimate | $2.67 |
| Surprise | Beat · +$0.24 (+9.0%) |
| Quarter ended | Sep 30, 2026 |
| Reported | Oct 29, 2026, after the close |
| Status | Confirmed · cross-checked Nov 2 |
EPS is as supplied by EODHD, in US dollars per share; whether it is adjusted or GAAP follows that source. ResMed’s fiscal year ends in June, so the quarter ended Sep 30, 2026 is its Q1 fiscal 2027.
ResMed EPS surprise history: last 5 quarters
ResMed beat the EPS estimate in 3 of its last 4 reports, with an average surprise of +2.4%.
| Report date | EPS est. | EPS actual | Surprise | Result | Move* |
|---|---|---|---|---|---|
| Oct 29, 2026 | $2.67 | $2.91 | – | – | – |
| Aug 6, 2026 | $2.89 | $2.95 | +2.1% | Beat | -5.4% |
| Apr 30, 2026 | $2.80 | $2.86 | +2.1% | Beat | -3.3% |
| Jan 29, 2026 | $2.72 | $2.81 | +3.3% | Beat | +0.2% |
| Oct 30, 2025 | $2.50 | $2.55 | +2.0% | In line | -2.7% |
*Move: change in the closing price from the last close before the report day to the close the day after it. It is filled in a few trading days after each report.
RMD stock reaction to the report
RMD moved -9.05% in the first session that reflects the report (close of Oct 29, 2026 $252.83 to close of Oct 30, 2026 $229.94). Since the report: -7.89% (latest close $232.88 on Nov 2, 2026, against $252.83 before the reaction).
Next RMD earnings report
ResMed has not announced its next earnings date yet. This page shows a date only once it is confirmed. See the RMD earnings calendar.
ATLAS fair value and signal for RMD
| Last price | $232.88 (+1.3%) |
|---|---|
| ATLAS fair value | $290.75 (range $205.01–$364.61) · price is 20% below it |
| Chance of a higher close in 1 month | 50% (normal range $217.00–$249.43) |
These are model outputs from the same valuation and calibrated model as the ResMed stock page. They describe an ordinary period and are not a forecast of any particular outcome.
ResMed Q1 fiscal 2027 earnings: frequently asked questions
Did ResMed beat earnings estimates for Q1 fiscal 2027?
ResMed reported EPS of $2.91 against an analyst estimate of $2.67: a beat of $0.24 (9.0%).
When did ResMed report Q1 fiscal 2027 results?
ResMed reported on Thursday, October 29, 2026, after the close, for the quarter ended Wednesday, September 30, 2026.
How often does RMD beat EPS estimates?
In its last 4 reports with a recorded result, ResMed beat the EPS estimate 3 times; the average surprise was +2.4%. Past results do not predict the next one.
How does ATLAS confirm a result?
A result is published only after it is cross-checked: the EODHD earnings calendar and the EODHD fundamentals feed must show the same EPS for the same fiscal period, or the same value must appear in two consecutive checks. Unconfirmed figures are never published. If the figures are revised later, this page updates.
Educational information, not investment advice. Disclaimer